India Diabetes Market - Forecast To 2030

India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Forecast to 2030

ID: MRFR/Pharma/2180-HCR | January 2023 | Region: Global | 60 Pages         

Diabetes Market Speak to Analyst Request a Free Sample

India Diabetes Market

India Diabetes Market is anticipated to reach USD 10,104 million by 2030 at 6.5% CAGR during the forecast period 2022-2030.

Segmentation
By Type Type 1 Type 2 Gestational diabetes
By Test Random blood sugar test Fasting blood sugar test Oral glucose tolerance test Initial glucose challenge test others
By Devices Blood glucose monitoring devices Diabetes management devices others
Key Players
Companies Profiled   Novo Nordisk A/S (Denmark)   USV Private Limited (India)   sanofi-aventis U.S   LLC (US)   Novartis AG (Switzerland)   Merck & Co.    Inc. (US)   Becton Dickinson and Company (US)
Drivers
Market Driving Forces   Increasing number of patients   Increasing urbanization   Healthcare infrastructure   Increasing spending on healthcare
Request a Free Sample

India Diabetes Market Overview


The Indian diabetes market is expected to gain a market value of USD 10,104 million by 2030 at a CAGR of 6.5% over the forecast period of 2022-2030.


A chronic metabolic condition known as diabetes results in high blood glucose levels, which seriously harm the heart, blood vessels, eyes, kidneys, and nerves. Drugs used to treat diabetes are known as diabetic therapies. They consist of oral diabetes medications and human insulin mimics.


The leading causes of diabetes in Indians are obesity, particularly central obesity, increased visceral fat brought on by physical inactivity, and diets high in calories, fat, and sugar. The most prevalent work culture that is still practiced in the nation, which involves consuming fast food while engaging in little to no physical exercise and spending hours in one position while seated, is a major factor in the rapid rise in diabetes incidence among India's working-age population. Additionally, rising diabetes prevalence and expanding use of insulin-delivery devices are propelling market expansion. In India, 77 million people were estimated to have diabetes in 2019, and by 2045, that number is expected to reach over 134 million. About 57% of these people are still undiagnosed. However, problems faced by poor individuals across India in managing diabetes care are major restraining factors for the market.


COVID-19 Analysis


The COVID-19 pandemic's second wave has severely impacted India. As of April 22, 2021, there were more than 315,000 new cases per day compared to 11,794 in the first week of February 2021. In many aspects, the COVID-19 pandemic's second wave was considered worse for diabetic people. However, the COVID-19 pandemic has had a good effect on the e-pharmacies industry; through this platform, it has been seen that sales of diabetes devices have increased. Diabetes devices are increasingly needed to successfully treat patients in hospitals and home care settings since people with diabetes are more likely to contract COVID-19.


Study objectives of India Diabetes Market:



  • To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Indian Diabetes Market

  • To provide insights about factors affecting the market growth

  • To analyze the India Diabetes Market based on various factors - price analysis, supply chain analysis, Porters Five Forces analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments

  • To provide detailed analysis of the market with respect to the current market size and future prospective

  • To provide detailed analysis of the market for segments by type, by test, by devices, by treatment, and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Market


 Segments:  


India Diabetes Market has been segmented on the basis of type which comprise Type 1, Type 2, and Gestational diabetes. On the basis of test market is segmented into Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others. On the basis of devices, it is segmented into Blood glucose monitoring devices, Diabetes management devices, and others. On the basis of treatment, the market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery and others.Recent Development



  • In March 2022, Medtronic India announced the launch of the MiniMed 780G System for diabetes management.

  • In July 2022, Zydus Lifesciences announced the launch of the top anti-diabetic drug molecule, Sitagliptin, in India.

  • In January 2022, Novo Nordisk announced the launch of the anti-diabetes pill Semaglutide in India.


Regional Analysis:


Considering the scenario of the Indian diabetes market, western region is believed to be the largest market for diabetes. Moreover the Eastern and Northern regions are also growing and second-largest market for India Diabetes. On the other hand, Southern Indian market is expected to grow at a significant rate in India diabetes during the forecasted period. Central region is likely to have a limited but moderate growth in the market.


Key Players:



  • Novo Nordisk A/S (Denmark)

  • USV Private Limited (India)

  • sanofi-aventis U.S

  • LLC (US)

  • Novartis AG (Switzerland)

  • Merck & Co., Inc. (US)

  • Becton Dickinson and Company (US)

  • Roche Diabetes Care, Inc.(US),

  • Johnson & Johnson Services, Inc.(us)

  • Bayer AG (Germany)

  • Ypsomed (Switzerland)


The report for India Diabetes Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.Intended Audience

  • Hospitals and Clinics

  • Diabetes drugs and devices manufacturers

  • Diabetes drugs and devices suppliers

  • Government and Independent Regulatory Authorities

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Potential Investors



Report Scope:

Report Attribute/Metric Details
  Market Size   USD10,104 million
  CAGR   6.5%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Test, Devices, Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novo Nordisk A/S (Denmark), USV Private Limited (India), sanofi-aventis U.S. LLC (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Becton Dickinson and Company (US), Roche Diabetes Care, Inc.(US),Johnson & Johnson Services, Inc.(us), Bayer AG (Germany), Ypsomed (Switzerland)
  Key Market Opportunities   Research and developments
  Key Market Drivers

  • Increasing number of patients
  • Increasing urbanization
  • Healthcare infrastructure
  • Increasing spending on healthcare


  • Speak to Analyst Ask for Customization